Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Humanized CD38 antibodies for cancer/autoimmune disease treatment

July 26, 1996

Multikine enters Canadian phase I/II trial

July 12, 1996

Antitumor vaccines described by University of Pennsylvania

July 5, 1996

Human Genome Sciences reports discovery of TNF-gamma

July 5, 1996

Virulizin undergoes phase I/II in pancreatic cancer

June 28, 1996

Multikine covered under Japanese patent

June 21, 1996

Actimmune metastatic renal cell carcinoma development terminated

June 14, 1996

E. Merck describes immunoconjugates

June 7, 1996

MuIGIF with interferon gamma production-stimulating properties identified

May 31, 1996

Results of MAb-B1 phase I/II trial announced

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.